Occurrence of Selected Generic Drugs 5

    Basic Details
    Date Posted
    Thursday, December 13, 2012
    Status
    Complete
    Medical Product
    alosetron HCL
    ambrisentan
    bosentan
    buprenorphine HCL
    eltrombopag olamine
    fentanyl
    hydromorphone HCL
    isotretinoin
    lenalidomide
    mifepristone
    oxycodone HCL
    romiplostim
    rosiglitazone maleate
    rosiglitazone/glimepiride
    rosiglitazone/metformin HCL
    thalidomide
    vigabatrin
    Description

    Summary table assessment of the use of Alosetron hydrochloride (HCL), Ambrisentan, Bosentan, Buprenorphine HCL, Buprenorphine HCL /Nalonxone HCL, Eltrombopag Olamine, Fentanyl, Hydromorphone HCL, Isotretinoin, Lenalidomide, Mifepristone, Oxycodone HCL, Romiplostim, Rosiglitazone Maleate, Rosiglitazone/Glimepiride, Rosiglitazone/Metformin HCL, Thalidomide, and Vigabatrin. Results were generated using the Mini-Sentinel Distributed Query Tool and the Dispensing Summary Table. Summary tables are precompiled stratified counts. Queries were executed in August 2011. This report includes data from 15 Data Partners.

    This document is an Excel spreadsheet that includes multiple layers of data configured using pivot tables. If you do not have Excel, click here to obtain a free version of Microsoft’s Excel Viewer.

    If you are using a web page screen reader and are un/able to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.

    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    CDER
    Time Period
    2001 - 2010
    Study Type
    Summary Table
    Assessment Type
    Exploratory Analyses
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)